RNA Outsourcing Resources

  1. Why US Pharma Manufacturing Delivers Strategic Value 7/28/2026

    Domestic pharmaceutical manufacturing strengthens supply chain resilience, simplifies distribution, speeds market response, and reduces risk by aligning production with key markets.

  2. How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic 3/9/2026

    Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

  3. Transitioning mRNA Production To cGMP Requires Early Process Engagement 10/9/2026

    Early choices in capping strategy, IVT conditions, raw materials, and downstream design shape yield, cost, and quality in mRNA manufacturing, and can determine whether a cGMP campaign succeeds.

  4. How Our Requalification Process Maintains Material Integrity 8/16/2023

    Review a breakdown of how to requalify every shipper for its impending transit and ensure your therapy material maintains integrity and safety during transportation.

  5. Solving Aseptic Filling Challenges For Your Advanced Therapeutics 8/20/2025

    Explore aseptic filling workcells, modalities, agency approvals, and insights from six expert users that offer a peer-driven look at industry innovation and benchmarks.

  6. Current Challenges In The Plasmid DNA Manufacturing Process 4/24/2026

    PolyA tail stability shapes mRNA potency, consistency, and manufacturability. Addressing integrity early reduces variability, simplifies workflows, and supports reliable clinical scale‑out.

  7. Why Bioanalysis Needs To Break Free From Manual Bottlenecks 9/2/2025

    Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.

  8. Sterile Injectables: Why Innovation Matters More Than Ever 1/15/2026

    New technologies and regulatory changes are shaping safer, more efficient filling processes. Discover why innovation is key to protecting patients and advancing therapies.

  9. How IntegriCell™ Services In Belgium Ensure Cell Viability, Supply Chain Integrity 4/28/2025

    he effectiveness of cell-based therapies hinges on preserving cell viability, stability, and consistency. However, inconsistencies in cryopreservation methods have undermined therapeutic success.

  10. When Local Variation Becomes Global Risk In Phase III 8/3/2026

    Late-stage therapy trials demand strict execution. Learn how local handling variations escalate into global risks and how early standardization safeguards therapeutic integrity and compliance.